AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23304688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of single implants (non-occlusal temporary crown within 24 hours)
Number of subjects: 20
Study 23304688 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of single implants (definitive crown 4 to 5 months later)
Number of subjects: 20
Study 19477488 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 12,800 IU for 7 days followed by 6,400 IU for a total of 3 months
Number of subjects: 67
Study 19477488 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day for 3 months
Number of subjects: 67
Study 17509947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 7665
Study 17509947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7665
Study 16094585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 50 mg
Number of subjects: 72
Study 12477510 — intervention group
Group type: EXPERIMENTAL
Intervention: PCBs and PEs exposure in infertile men
Number of subjects: 21
Study 12477510 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 men with normal semen analyses)
Number of subjects: 21
Study 12477510 — intervention group
Group type: EXPERIMENTAL
Intervention: Total motile sperm counts in infertile men
Number of subjects: 21
Study 9661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone matrix IGF‐I concentration
Number of subjects: 533
Study 9661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone matrix IGF‐II concentration
Number of subjects: 533
Study 9661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF‐I concentration
Number of subjects: 533
Study 9661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone matrix IGF‐I
Number of subjects: 533
Study 7660438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (60mg elemental iron per day)
Number of subjects: 497
Study 7660438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 2468963 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily dosages of enalapril (40 mg and, when necessary, 60 mg)
Number of subjects: 46
Study 2468963 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day enalapril and hydrochlorothiazide (25 mg/day and, when necessary, 50 mg)
Number of subjects: 46
Study 544571 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic irradiation using a moving-strip technique, 2250 rad in 10 fractions, starting with pelvic irradiation.
Number of subjects: 0
Study 544571 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation alone or followed by chlorambucil therapy.
Number of subjects: 0
Study 30370752 — intervention group
Group type: EXPERIMENTAL
Intervention: LATE program (land-based and aquatic trunk exercises)
Number of subjects: 29
Study 30370752 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 29
Study 28176305 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal cerclage
Number of subjects: 67
Study 28176305 — intervention group
Group type: COMPARATOR
Intervention: Control group (high or low transvaginal cerclage)
Number of subjects: 67
Study 25460265 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked images of spiders (VBE)
Number of subjects: 86
Study 25460265 — intervention group
Group type: COMPARATOR
Intervention: Masked images of flowers (Control)
Number of subjects: 86
Study 23481528 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge (n=150)
Number of subjects: 298
Study 23481528 — intervention group
Group type: COMPARATOR
Intervention: Next-day discharge (n=148)
Number of subjects: 298
Study 23481528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 298
Study 20672243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/day)
Number of subjects: 131
Study 20672243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 19169146 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in combination with meperidine
Number of subjects: 200
Study 19169146 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 200
Study 19776569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with NaF toothpaste (A)
Number of subjects: 20
Study 19776569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with NaF toothpaste followed by professional flossing (B)
Number of subjects: 20
Study 19776569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with NaF toothpaste followed by professional flossing and rinsing with NaF mouthwash (C)
Number of subjects: 20
Study 16368051 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day (O group)
Number of subjects: 89
Study 16368051 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg/day (F group)
Number of subjects: 89
Study 16368051 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid plus micronised fenofibrate 200 mg/day (OF group)
Number of subjects: 89
Study 16368051 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 89
Study 12507240 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐coated threaded implants
Number of subjects: 120
Study 12507240 — intervention group
Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 120
Study 9814501 — intervention group
Group type: EXPERIMENTAL
Intervention: RET/PTC rearrangements in occult papillary thyroid microcarcinomas
Number of subjects: 21
Study 9814501 — intervention group
Group type: EXPERIMENTAL
Intervention: RET/PTC rearrangements in clinically evident tumors
Number of subjects: 21
Study 9814501 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry correlation with RT-PCR
Number of subjects: 21
Study 9814501 — intervention group
Group type: EXPERIMENTAL
Intervention: RET/PTC expression prevalence
Number of subjects: 21
Study 9814501 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversity of RET/PTC profiles in multifocal disease
Number of subjects: 21
Study 9098296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracaine
Number of subjects: 44
Study 9098296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9098296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 2713216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (120 mg orally)
Number of subjects: 29
Study 2713216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 887644 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (Melleril-Sandoz)
Number of subjects: 26
Study 887644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11368483 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnstone pressure splints (JPSs) combined with Bobath's neurodevelopmental therapy (NDT)
Number of subjects: 34
Study 11368483 — intervention group
Group type: COMPARATOR
Intervention: NDT alone
Number of subjects: 34
Study 30986795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection of vaginal swabs without nurse assistance
Number of subjects: 96
Study 30986795 — intervention group
Group type: COMPARATOR
Intervention: Self-collection of vaginal swabs with nurse assistance
Number of subjects: 96
Study 30986795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection of vaginal swabs (both arms)
Number of subjects: 96
Study 30986795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis testing
Number of subjects: 96
Study 29388901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 6
Study 26896345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 12.5 μg/kg (D12.5)
Number of subjects: 7
Study 26896345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 μg/kg (D25)
Number of subjects: 7
Study 26896345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 μg/kg and MK‐467 600 μg/kg (D25M600)
Number of subjects: 7
Study 26896345 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐467 300 μg/kg (M300)
Number of subjects: 7
Study 26896345 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐467 in D25M600
Number of subjects: 7
Study 25364817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 0
Study 22490161 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 78
Study 20379030 — intervention group
Group type: EXPERIMENTAL
Intervention: Beautifil II (containing S-PRG filler)
Number of subjects: 0
Study 20379030 — intervention group
Group type: COMPARATOR
Intervention: Clearfil AP-X
Number of subjects: 0
Study 20379030 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250
Number of subjects: 0
Study 17272731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prophylactic haloperidol treatment
Number of subjects: 101
Study 17272731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 16136045 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 with histamine dihydrochloride (HDC)
Number of subjects: 104
Study 16136045 — intervention group
Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 104
Study 12433233 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR (150 mg for week 1, 300 mg for weeks 2 to 5)
Number of subjects: 24
Study 12433233 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR
Number of subjects: 24
Study 12433233 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 10453828 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg four hourly (to a maximum of four doses)
Number of subjects: 211
Study 10453828 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone gel 1 mg six hourly (to a maximum of three doses)
Number of subjects: 211
Study 10453828 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 211
Study 10453828 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 211
Study 8535660 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (MRS)
Number of subjects: 30
Study 2199281 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogues (B9Asp + B27Glu or B10Asp)
Number of subjects: 0
Study 2199281 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 0
Study 69194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramisole every 4 months
Number of subjects: 154
Study 69194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 30838777 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical testing strategies for treatment efficacy in marker-positive subpopulations
Number of subjects: 0
Study 30838777 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical testing strategies for treatment efficacy in marker-negative patients
Number of subjects: 0
Study 30838777 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical testing strategies for assessing marker accuracy
Number of subjects: 0
Study 30838777 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical testing strategies based on probabilities of asserting treatment efficacy
Number of subjects: 0
Study 29442544 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV with supplemental pyridoxine
Number of subjects: 0
Study 29442544 — intervention group
Group type: COMPARATOR
Intervention: LEV only (control group)
Number of subjects: 0
Study 27115337 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 29
Study 27115337 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 29
Study 23742666 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (writing for 20 minutes on four occasions about deepest thoughts and feelings regarding their most stressful/traumatic event)
Number of subjects: 116
Study 23742666 — intervention group
Group type: COMPARATOR
Intervention: Control topic (writing about a control topic)
Number of subjects: 116
Study 22591134 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for YHC professionals to increase self-efficacy and skills in discussing weight issues
Number of subjects: 16
Study 22591134 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved communication skills for YHC professionals
Number of subjects: 16
Study 22591134 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased parental awareness of child's overweight
Number of subjects: 16
Study 21126973 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided percutaneous coronary intervention
Number of subjects: 1005
Study 21126973 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided percutaneous coronary intervention
Number of subjects: 1005
Study 17616452 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 120 microg/day p.o.
Number of subjects: 80
Study 17616452 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (TS) 40 mg/day p.o.
Number of subjects: 80
Study 17616452 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) plus Telmisartan (TS)
Number of subjects: 80
Study 17616452 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 80
Study 15812750 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 35
Study 15812750 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 35
Study 11158473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cys‐LT receptor antagonists (Cys‐LTRA) such as montelukast
Number of subjects: 0
Study 11158473 — intervention group
Group type: EXPERIMENTAL
Intervention: LT modifiers
Number of subjects: 0
Study 9554431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg/kg
Number of subjects: 20
Study 9554431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 20
Study 9554431 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study 7930028 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone infusion at 5 micrograms/kg/min
Number of subjects: 12
Study 7930028 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone infusion at 10 micrograms/kg/min
Number of subjects: 12
Study 3276999 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg (n = 10)
Number of subjects: 16
Study 3276999 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 mg (n = 4)
Number of subjects: 16
Study 3276999 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg (n = 2)
Number of subjects: 16
Study 3276999 — intervention group
Group type: COMPARATOR
Intervention: Clonidine detoxification (successful)
Number of subjects: 16
Study 3276999 — intervention group
Group type: COMPARATOR
Intervention: Clonidine detoxification (failures)
Number of subjects: 16
Study 31247017 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy (4 sessions, once every two weeks for seven weeks)
Number of subjects: 56
Study 31247017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 56
Study 28325221 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment (IHT)
Number of subjects: 133
Study 28325221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 133
Study 28325221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 25897569 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour nightly CPAP treatment
Number of subjects: 39
Study 25897569 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 39
Study 23732713 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (n = 386)
Number of subjects: 778
Study 23732713 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (n = 400)
Number of subjects: 778
Study 23732713 — intervention group
Group type: COMPARATOR
Intervention: Composite of all VTE and clinically significant bleeding events (Aspirin vs Dalteparin)
Number of subjects: 778
Study 21447945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration group
Number of subjects: 150
Study 21447945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 18416085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuscoporia obliqua
Number of subjects: 14
Study 18416085 — intervention group
Group type: COMPARATOR
Intervention: Control (diet-treated type 2 diabetic patients)
Number of subjects: 14
Study 18416085 — intervention group
Group type: COMPARATOR
Intervention: Control (age- and sex-matched controls)
Number of subjects: 14
Study 16865013 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide 1% 3 times daily
Number of subjects: 64
Study 16865013 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol hydrochloride 2% twice daily
Number of subjects: 64
Study 16865013 — intervention group
Group type: COMPARATOR
Intervention: latanoprost-dorzolamide combination
Number of subjects: 64
Study 16865013 — intervention group
Group type: COMPARATOR
Intervention: latanoprost-carteolol combination
Number of subjects: 64
Study 12627729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (6 g nightly, adjustable between 3 to 9 g)
Number of subjects: 118
Study 10846514 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched foods
Number of subjects: 143
Study 10846514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 143
Study 10846514 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched foods
Number of subjects: 143
Study 10846514 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither enriched foods nor exercise)
Number of subjects: 143
Study 9400511 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/day folic acid
Number of subjects: 95
Study 9400511 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/day folic acid
Number of subjects: 95
Study 9400511 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/day folic acid
Number of subjects: 95
Study 9400511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7959385 — intervention group
Group type: EXPERIMENTAL
Intervention: Epididymal fine needle aspiration (EFNA)
Number of subjects: 17
Study 3296628 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (3‐5 g/kg bw for 24 h)
Number of subjects: 18
Study 3296628 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled protein intake (2‐2.5 g/kg bw)
Number of subjects: 18
Study 3296628 — intervention group
Group type: COMPARATOR
Intervention: Low protein intake (1.2 g/kg bw for 12 days)
Number of subjects: 18
Study 29703287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral combination of 2 mydriatics and 1 anesthetic (Mydrane)
Number of subjects: 730
Study 29703287 — intervention group
Group type: COMPARATOR
Intervention: Topical regimen (control group)
Number of subjects: 730
Study 27855085 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture pretreatment followed by 4 cycles of letrozole
Number of subjects: 384
Study 27855085 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (control group)
Number of subjects: 384
Study 24656727 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 23
Study 24656727 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 23
Study 23516294 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional working memory training for 20 days
Number of subjects: 0
Study 23516294 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 0
Study 20586697 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (group and individual treatment, dietary counseling, cognitive-behavioral therapy)
Number of subjects: 2375
Study 20586697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic strategies (metformin, fenfluramine, sibutramine, topiramate, reboxetine)
Number of subjects: 2375
Study 20586697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2375
Study 18078958 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the ureteroileal anastomosis
Number of subjects: 54
Study 18078958 — intervention group
Group type: COMPARATOR
Intervention: No stenting of the ureteroileal anastomosis
Number of subjects: 54
Study 16888042 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtrained group (OT) performing 10 x 1 at 100% 1 RM daily for 2 weeks
Number of subjects: 16
Study 16888042 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con) performing normal training 2 days/week
Number of subjects: 16
Study 11822985 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-directed therapy
Number of subjects: 0
Study 11822985 — intervention group
Group type: EXPERIMENTAL
Intervention: Current chemotherapy approaches
Number of subjects: 0
Study 9659069 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 2303
Study 9659069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 2303
Study 9659069 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 2303
Study 9659069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2303
Study 9118364 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency needle ablation (TUNA technique)
Number of subjects: 15
Study 2497058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg tid)
Number of subjects: 10
Study 2497058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14468 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (600 mg daily)
Number of subjects: 55
Study 14468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (15 mg daily)
Number of subjects: 55
Study 14468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6163829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylglycine (DMG)
Number of subjects: 20
Study 6163829 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 30616596 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 225
Study 30616596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225